Joinn Laboratories (06127) announced its first-quarter performance, with a net profit attributable to the parent of approximately 41.1195 million yuan, turning losses into profits year-on-year.

Joinn Laboratories (06127) announced its performance in the first quarter of 2025, with operating income of approximately RMB 287 million, a decrease of 11.54% year-on-year; net profit attributable to shareholders of the listed company was approximately RMB 41.1195 million, turning from a loss to a profit; basic earnings per share were RMB 0.05. The announcement stated that the increase in net profit was mainly due to more losses from the fair value changes of biological assets in the same period of the previous year. Affected by changes in market environment, adjustments in industry competition landscape, and fluctuations in customer demand, the company's new order amount for the reporting period was approximately RMB 430 million, and the amount of orders on hand as of the end of the reporting period was approximately RMB 2.2 billion. The execution of orders on hand by the company is affected by various factors, so investors should pay attention to investment risks.